| SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase BL Bennett, DT Sasaki, BW Murray, EC O'Leary, ST Sakata, W Xu, ... Proceedings of the National Academy of Sciences 98 (24), 13681-13686, 2001 | 3011 | 2001 |
| IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation F Mercurio, H Zhu, BW Murray, A Shevchenko, BL Bennett, J Li, ... Science 278 (5339), 860-866, 1997 | 2691 | 1997 |
| Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine … DD Hu-Lowe, HY Zou, ML Grazzini, ME Hallin, GR Wickman, ... Clinical Cancer Research 14 (22), 7272-7283, 2008 | 684 | 2008 |
| IκB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex F Mercurio, BW Murray, A Shevchenko, BL Bennett, DB Young, JW Li, ... Molecular and cellular biology 19 (2), 1526-1538, 1999 | 448 | 1999 |
| Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors M McTigue, BW Murray, JH Chen, YL Deng, J Solowiej, RS Kania Proceedings of the National Academy of Sciences 109 (45), 18281-18289, 2012 | 432 | 2012 |
| Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors M McTigue, BW Murray, JH Chen, YL Deng, J Solowiej, RS Kania Proceedings of the National Academy of Sciences 109 (45), 18281-18289, 2012 | 432 | 2012 |
| Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19 RL Hoffman, RS Kania, MA Brothers, JF Davies, RA Ferre, KS Gajiwala, ... Journal of medicinal chemistry 63 (21), 12725-12747, 2020 | 414 | 2020 |
| Spectrum and degree of CDK drug interactions predicts clinical performance P Chen, NV Lee, W Hu, M Xu, RA Ferre, H Lam, S Bergqvist, J Solowiej, ... Molecular cancer therapeutics 15 (10), 2273-2281, 2016 | 341 | 2016 |
| Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth BW Murray, C Guo, J Piraino, JK Westwick, C Zhang, J Lamerdin, ... Proceedings of the National Academy of Sciences 107 (20), 9446-9451, 2010 | 328 | 2010 |
| PAK signaling in oncogenesis PR Molli, DQ Li, BW Murray, SK Rayala, R Kumar Oncogene 28 (28), 2545-2555, 2009 | 264 | 2009 |
| Axitinib effectively inhibits BCR-ABL1 (T315I) with a distinct binding conformation T Pemovska, E Johnson, M Kontro, GA Repasky, J Chen, P Wells, ... Nature 519 (7541), 102-105, 2015 | 262 | 2015 |
| JNKK1 organizes a MAP kinase module through specific and sequential interactions with upstream and downstream components mediated by its amino-terminal extension Y Xia, Z Wu, B Su, B Murray, M Karin Genes & development 12 (21), 3369-3381, 1998 | 251 | 1998 |
| Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance PA Schwartz, P Kuzmic, J Solowiej, S Bergqvist, B Bolanos, C Almaden, ... Proceedings of the National Academy of Sciences 111 (1), 173-178, 2014 | 249 | 2014 |
| p38-2, a novel mitogen-activated protein kinase with distinct properties B Stein, MX Yang, DB Young, R Janknecht, T Hunter, BW Murray, ... Journal of Biological Chemistry 272 (31), 19509-19517, 1997 | 244 | 1997 |
| Protein kinase biochemistry and drug discovery PA Schwartz, BW Murray Bioorganic chemistry 39 (5-6), 192-210, 2011 | 213 | 2011 |
| Mechanism of human α-1, 3-fucosyltransferase V: glycosidic cleavage occurs prior to nucleophilic attack BW Murray, V Wittmann, MD Burkart, SC Hung, CH Wong Biochemistry 36 (4), 823-831, 1997 | 206 | 1997 |
| Mechanism of human α-1, 3-fucosyltransferase V: glycosidic cleavage occurs prior to nucleophilic attack BW Murray, V Wittmann, MD Burkart, SC Hung, CH Wong Biochemistry 36 (4), 823-831, 1997 | 206 | 1997 |
| Chemo-enzymatic synthesis of fluorinated sugar nucleotide: useful mechanistic probes for glycosyltransferases MD Burkart, SP Vincent, A Düffels, BW Murray, SV Ley, CH Wong Bioorganic & medicinal chemistry 8 (8), 1937-1946, 2000 | 186 | 2000 |
| Mechanism and specificity of human α-1, 3-fucosyltransferase V BW Murray, S Takayama, J Schultz, CH Wong Biochemistry 35 (34), 11183-11195, 1996 | 170 | 1996 |
| Synergistic inhibition of human α-1, 3-fucosyltransferase V L Qiao, BW Murray, M Shimazaki, J Schultz, CH Wong Journal of the American Chemical Society 118 (33), 7653-7662, 1996 | 160 | 1996 |
